JP2006510610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006510610A5 JP2006510610A5 JP2004548439A JP2004548439A JP2006510610A5 JP 2006510610 A5 JP2006510610 A5 JP 2006510610A5 JP 2004548439 A JP2004548439 A JP 2004548439A JP 2004548439 A JP2004548439 A JP 2004548439A JP 2006510610 A5 JP2006510610 A5 JP 2006510610A5
- Authority
- JP
- Japan
- Prior art keywords
- infected
- hiv
- strain
- viral replication
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000029812 viral genome replication Effects 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 2
- 102200009479 ACO2 L74V Human genes 0.000 claims 1
- 102200060142 DHX33 K103N Human genes 0.000 claims 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 claims 1
- 102000033147 ERVK-25 Human genes 0.000 claims 1
- 102200080009 GALNS M41L Human genes 0.000 claims 1
- 102200017756 PCK1 K70R Human genes 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 102220011161 rs727504317 Human genes 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (14)
- ＨＩＶの耐性株に感染した細胞中でのウイルス複製を阻害する方法において、式Ｉ
の化合物又はその薬学的に許容可能な塩のウイルス複製阻害量を感染細胞に投与することを含んでなる方法。 - ＸはＢｒである請求項１に記載の方法。
- ＸはＣｌである請求項１に記載の方法。
- ＸはＩである請求項１に記載の方法。
- ＸはＮＯ ２ である請求項１に記載の方法。
- Ｒ２は、-ＮＨＣＨ(ＣＨ３)ＣＯＯＣＨ３である請求項１に記載の方法。
- ＨＩＶの耐性株がＡ１７又はＡ１７-Ｖである請求項１に記載の方法。
- 耐性ＨＩＶ株が、少なくとも一の治療過程に応答しないか又は応答しなかった感染個体から得られた臨床分離株である請求項１に記載の方法。
- ＨＩＶ株が非Ｂサブタイプである請求項８に記載の方法。
- 感染した細胞への上記投与が、動物への投与を含んでなる請求項１に記載の方法。
- 動物がヒトである請求項１０に記載の方法。
- ウイルス複製阻害量が約１〜約５００ｍｇ／ｋｇ動物体重である請求項１１に記載の方法。
- ウイルス複製阻害量が約１０〜約１００ｍｇ／ｋｇ動物体重である請求項１２に記載の方法。
- 上記分離株が、変異型逆転写酵素を有するＨＩＶ株に感染しており、該変異が、Ｍ４１Ｌ、Ｄ６７Ｎ、Ｋ７０Ｒ、Ｌ７４Ｖ、Ｋ１０３Ｎ、Ｖ１０６Ｎ／Ａ、Ｅ１３８Ｋ、Ｙ１８１Ｃ、Ｙ１８８Ｈ／Ｌ、Ｔ２１５Ｙ／Ｆ／Ｄの一又は複数を含む請求項１に記載の方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/281,333 US7144874B2 (en) | 2002-10-25 | 2002-10-25 | Aryl phosphate derivatives of d4T having activity against resistant HIV strains |
| PCT/US2003/033622 WO2004040002A2 (en) | 2002-10-25 | 2003-10-24 | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ACTIVITY AGAINST RESISTANT HIV STRAINS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510610A JP2006510610A (ja) | 2006-03-30 |
| JP2006510610A5 true JP2006510610A5 (ja) | 2006-12-14 |
Family
ID=32174602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004548439A Pending JP2006510610A (ja) | 2002-10-25 | 2003-10-24 | 耐性ＨＩＶ株に対して活性を有するｄ４Ｔのアリールホスフェート誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7144874B2 (ja) |
| EP (1) | EP1594976A4 (ja) |
| JP (1) | JP2006510610A (ja) |
| AU (1) | AU2003286621A1 (ja) |
| CA (1) | CA2502837A1 (ja) |
| WO (1) | WO2004040002A2 (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60020891T2 (de) * | 2000-11-13 | 2005-12-08 | Parker Hughes Institute, St. Paul | Arylphosphatderivate von d4t |
| US20060046972A1 (en) * | 2004-08-31 | 2006-03-02 | Parker Hughes Institute | Cytotoxic nucleoside analog compound 003 for treating cancer |
| GB0623493D0 (en) * | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4841039A (en) | 1986-05-01 | 1989-06-20 | Emory University | 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents |
| US5672698A (en) * | 1993-11-15 | 1997-09-30 | Bristol-Myers Squibb Co. | Preparation of 2',3'-didehydro-3'-deoxythymidine from 5-methyluridine |
| US5659023A (en) * | 1995-02-01 | 1997-08-19 | Gilead Sciences, Inc. | Nucleotide analogues |
| US6030957A (en) * | 1998-06-29 | 2000-02-29 | Wayne Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
| DE60020891T2 (de) * | 2000-11-13 | 2005-12-08 | Parker Hughes Institute, St. Paul | Arylphosphatderivate von d4t |
| US20030236218A1 (en) * | 2002-06-12 | 2003-12-25 | Uckun Fatih M. | Aryl phosphate derivatives of d4T with selective activity against adenovirus and HIV |
-
2002
- 2002-10-25 US US10/281,333 patent/US7144874B2/en not_active Expired - Fee Related
-
2003
- 2003-10-24 JP JP2004548439A patent/JP2006510610A/ja active Pending
- 2003-10-24 CA CA002502837A patent/CA2502837A1/en not_active Abandoned
- 2003-10-24 AU AU2003286621A patent/AU2003286621A1/en not_active Abandoned
- 2003-10-24 EP EP03777827A patent/EP1594976A4/en not_active Withdrawn
- 2003-10-24 WO PCT/US2003/033622 patent/WO2004040002A2/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004509061A5 (ja) | ||
| RU2002120922A (ru) | Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием | |
| JP3133345B2 (ja) | Ｈｉｖに対して活性な連結環状ポリアミン | |
| EP2278960B1 (en) | Dosing regimen for a selective sip1 receptor agonist | |
| JP2003526662A5 (ja) | ||
| JP2003501474A5 (ja) | ||
| JP2004538303A5 (ja) | ||
| CA2088352A1 (en) | Tnf inhibitors | |
| JP2010505831A5 (ja) | ||
| JP2002519425A5 (ja) | ||
| JP2009525265A5 (ja) | ||
| JP2004506682A5 (ja) | ||
| JP2001520994A5 (ja) | ||
| ES2488821T3 (es) | Proceso de preparación de un compuesto antiviral | |
| JP2006510610A5 (ja) | ||
| JP2005514456A5 (ja) | ||
| JP7453399B2 (ja) | Ｈｉｖ感染症を治療するための四環式化合物及びその使用 | |
| EP1246832A1 (en) | Treatment of viral infections using levovirin?tm | |
| JP2007507472A5 (ja) | ||
| HUT56855A (en) | Process for producing antiviral pharmaceutical compositions | |
| JP2004538278A5 (ja) | ||
| Wainberg et al. | Vaccine and antiviral strategies against infections caused by human immunodeficiency virus. | |
| JP2005516066A5 (ja) | ||
| JPH0415766B2 (ja) | ||
| JP2002540149A (ja) | ウイルス感染治療のためのカルバミン酸エステル誘導体の使用法 |